Williams, Thomas http://orcid.org/0000-0002-8197-0177
Alexander, Sarah
Blackstone, James
De Angelis, Floriana
John, Nevin
Doshi, Anisha
Beveridge, Judy
Braisher, Marie
Gray, Emma
Chataway, Jeremy
,
Article History
Received: 29 April 2022
Accepted: 22 July 2022
First Online: 9 August 2022
Declarations
:
: Ethical approval was granted for the MS-SMART and MS-STAT2 clinical trials by UK NHS Research Ethics Committee 13/SS/0007 and 17/LO/1509, respectively. All participants gave written informed consent.
: NA; no individual patient data included.
: TW: has received honoraria for educational talks for Novartis and MerckSA: no relevant conflict of interest to declareJB: no relevant conflict of interest to declareFDA: no relevant conflict of interest to declareNJ: no relevant conflict of interest to declareAD: no relevant conflict of interest to declareJB: no relevant conflict of interest to declareMB: no relevant conflict of interest to declareEG: Assistant Director of Research at the MS Society (UK); no relevant conflict of interest to declareJC: In the last 3 years, JC has received support from the Efficacy and Mechanisms Evaluation Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by the Canadian MS society. He is a local principal investigator for commercial trials funded by Actelion, Novartis and Roche and has taken part in advisory boards/consultancy for Azadyne, Janssen, Merck, NervGen, Novartis and Roche.